Syndax Pharmaceuticals, Inc.
NASDAQ:SNDXBiotechnology
+$0.13 today
- Market cap
- $770.64M
- Beta
- 0.39
- P/E (TTM)
- -6.8
- EPS (TTM)
- -$2.81
Volume 3.46M
Average 1.70M
SNDX Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Syndax Pharmaceuticals, Inc.NASDAQ: SNDX
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash growth accelerates
Q1 FY2026 net change in cash of $4.04M (cash outflow) rose 4385.6% year over year, ahead of the -159.0% change in trailing-twelve-month net change in cash. Over 3 fiscal years it compounded at -49.3% a year.
Context
- Net change in cash amounted to 11.2% of revenue in FY2025, down 585.6 pp from a year earlier.
- Net change in cash increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +4385.6% holds above the trailing-twelve-month pace of -159.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- (19.27M) USD
- Year-over-year change
- +86.4%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (19.27M) | +86.4% |
| FY2024 | 2024-12-31 | (141.31M) | -163.9% |
| FY2023 | 2023-12-31 | 221.14M | +249.8% |
| FY2022 | 2022-12-31 | (147.61M) | -238.3% |
| FY2021 | 2021-12-31 | 106.72M | — |
Net Change in Cash vs competitors
How SNDX compares with its peers on the latest reported figures
- SNDX's LTM Mar 2026 net change in cash of $23.22M is the 7th largest of the 11 companies compared; the peer median is $3.59M.
- Its year-over-year change of -159.0% is the 7th highest of 11, against a peer median of -88.2%.
- Net change in cash amounts to 10.7% of revenue for SNDX, versus a peer median of 50.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $641.62M | +3223.9% | — | 91.4% | |
| LTM Jun 2026 | $98M | -206.5% | +7.5% | 83.8% | |
| LTM Mar 2026 | $79.05M | -221.2% | +105.0% | 50.3% | |
| LTM Dec 2025 | $49.29M | -166.1% | — | — | |
| LTM Jun 2026 | $48.53M | -77.3% | — | 28.6% | |
| LTM Sep 2026 | $35.63M | +161.9% | — | 13.4% | |
| LTM Mar 2026 | $23.22M | -159.0% | -49.3% | 10.7% | |
| LTM Mar 2026 | $18.28M | -258.5% | +28.0% | 51.4% | |
| LTM Mar 2026 | $11.67M | +77.5% | -84.4% | — | |
| LTM Mar 2026 | $7.06M | +200.5% | -55.8% | — | |
| LTM Jun 2026 | $126K | -99.1% | — | 0.1% | |
| Peer median (excluding SNDX) | $3.59M | -88.2% | +7.5% | 50.3% | |
Competitors are the stored peer set for SNDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 24.93M | (149.34M) | (209.36M) | (318.76M) | (285.42M) |
| Depreciation & Amortization | 43K | 33K | 12K | 8K | 6K |
| Deferred Income Tax | 255K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 13.32M | 16.02M | 30.95M | 43.03M | 47.5M |
| Change in Working Capital | (9.6M) | 1.66M | 31.86M | 13.27M | (79.32M) |
| Accounts Receivables | 0 | (3.47M) | 10.71M | (11.24M) | (36.83M) |
| Inventory | 0 | 3.47M | 0 | (366K) | (32.09M) |
| Accounts Payables | 2.16M | (1.32M) | 5.61M | 1.67M | 4.95M |
| Other Working Capital | (11.76M) | 2.98M | 15.54M | 23.21M | (15.35M) |
| Other Non-Cash Items | 187K | (2.05M) | (14.06M) | (12.45M) | (5.75M) |
| Operating Cash Flow | 29.13M | (133.68M) | (160.6M) | (274.9M) | (322.98M) |
| Capital Expenditures | (129K) | (225K) | 0 | 0 | (187K) |
| Acquisitions (Net) | 40.74K | 225K | 0 | 0 | 0 |
| Purchases of Investments | (294.72M) | (495.35M) | (354.61M) | (557.05M) | (195.81M) |
| Sales of Investments | 253.98M | 308.93M | 472.22M | 337.28M | 486.03M |
| Other Investing Activities | (40.74K) | 225K | 0 | 0 | 0 |
| Investing Cash Flow | (40.87M) | (186.19M) | 117.61M | (219.78M) | 290.04M |
| Debt Repayment | 0 | (21M) | 0 | 0 | 0 |
| Common Stock Issued | 86.34M | 181.39M | 258.09M | 9.72M | 13.68M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 32.13M | 11.86M | 6.04M | 343.65M | 0 |
| Financing Cash Flow | 118.46M | 172.25M | 264.13M | 353.37M | 13.68M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 106.72M | (147.61M) | 221.14M | (141.31M) | (19.27M) |
| Free Cash Flow | 29M | (133.9M) | (160.6M) | (274.9M) | (323.17M) |
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
Intrinsic Alpha fair value
Locked
Current Price
$8.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.